News Column

Advaxis, Inc. - “Pediatric Osteosarcoma: The First Indication in the ADXS-cHER2 Franchise”

May 7, 2014



Category: Baystreet Newswire

Company: Market Exclusive

ID: 415330

Date: Wednesday, May 07, 2014

Ticker: NASDAQ:ADXS

PRINCETON, NJ / ACCESSWIRE / May 7, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. Following the Company's announcement to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric bone cancer, Mr. O'Connor further discusses strategies to pursue the pediatric osteosarcoma indication. In his blog he states, "Given the encouraging canine osteosarcoma data, the logical next step in development for ADXS-cHER2 is human osteosarcoma." Read the full blog post from Mr. Daniel J. O'Connor on TheChairmansBlog.com (http://www.thechairmansblog.com/advaxis/daniel-oconnor/pediatric-osteosarcoma-first-indication-adxs-cher2-franchise/). About Advaxis, Inc.Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis's immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses. ADXS-HPV, Advaxis's lead immunotherapy for the treatment of HPV-associated cancers, has demonstrated improved survival and objective tumor responses in a Phase 2 trial in 110 patients with recurrent cervical cancer. Advaxis is now planning the registrational program for ADXS-HPV. ADXS-HPV is also being evaluated in other HPV-associated cancers including a Phase 2 in advanced cervical cancer, a Phase 1/2 in head and neck cancer, and a Phase 1/2 in anal cancer. ADXS-HPV has orphan drug status for both anal and head and neck cancers. As part of its global commercialization strategy to enter into regional licensing deals with other market dominant biopharmaceutical companies in territories where there is a high prevalence of HPV-associated cancers, Advaxis has granted exclusive licenses for the development and commercialization of ADXS-HPV in Asia and India. ADXS-cHER2 is an immunotherapy for the treatment of HER2 overexpressing cancers (such as breast, gastric, esophageal, and other cancers in humans and for osteosarcoma in canines). Advaxis's lead animal-health immunotherapy, ADXS-cHER2, has demonstrated encouraging survival data in a Phase 1 trial in canine osteosarcoma. These data provide the rationale to advance this same immunotherapy into a Phase 1 clinical trial in women with HER2-positive breast cancer. The Company is preparing an IND submission for ADXS-cHER2 in breast cancer in 2014. Advaxis has created more than 20 distinct immunotherapies based on its platform, either directly or through strategic collaborations with recognized cancer centers of excellence. We have clinical research collaborations with the University of Pennsylvania, Brown University, the Georgia Regents University Cancer Center, the Icahn School of Medicine at Mount Sinai, and others. For more information, visit http://www.advaxis.com/. About TheChairmansBlog.comTheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. http://www.thechairmansblog.com/ SOURCE: Advaxis, Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: ACCESSWIRE (Canada)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters